Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model

Figure 4 Erlotinib treatment inhibited cell proliferation. A: Representative immunohistochemistry for BrdU incorporation in normal, vehicle-treated and erlotinib-treated animals (200 x). B: Cell proliferation in erlotinib-treated animals was less than that shown in vehicle-treated animals and not significantly different from normal animals (^aP < 0.05; n = 10 ± SE).